Logo Image
|Articles|September 28, 2022

Healthcare Businesswomen's Association recognizes Delix Therapeutics and Pfizer UK

The companies have shown a commitment to enhancing greater equity for women.

To showcase the impactful commitment and outcomes of equitable practices for women in the workplace, the Healthcare Businesswomen’s Association (HBA) recognizes Delix Therapeutics and Pfizer UK Ltd., for initiatives working to close the gender gap in the healthcare and life science industries. The awards will be presented on Thursday, November 3, in conjunction with HBA’s Annual Conference in Philadelphia.

HBA’s Advancement. Commitment. Engagement. (ACE) Awards recognize companies committed to ensuring that gender diversity and leadership opportunities for women are part of their organizational DNA. An independent panel of healthcare industry leaders selects ACE Award recipients for their excellence in advancing their female talent and removing the systemic barriers preventing timely progress to parity. Award criteria include measurable results, business performance, stewardship, execution, and sustainability.

Read more here.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more